Latest news

• Pfizer gets EU nod for Tagrisso rival Vizimpro

  Last November, the drugmaker claimed FDA approval for Xalkori follow-up Lorbrena (lorlatinib) in second-line ALK-positive NSCLC and SMO inhibitor Daurismo (glasdegib) for acute myeloid leukaemia, while in October ... it got a green light for PARP

• Pfizer claims rapid FDA nod for Lorbrena

  The FDA has granted approval to Pfizer's next generation ALK inhibitor lung cancer treatment Lorbrena, which will help it defend its presence in the market. ... Follow-up ALK inhibitors are important in this treatment pathway, as many experience tumour

• Pfizer’s flat sales focus investor attention on M&A

  Among the highlights cited by Read on the call were oncology drugs talazoparib - a PARP inhibitor due for filing shortly for breast cancer - along with ALK/ROS1 inhibitor lorlatinib and EGFR ... inhibitor dacomitinib for lung cancer, which are due for

• Pfizer files third-gen ALK inhibitor for lung cancer

  Pfizer has filed for approval of its third-generation ALK inhibitor lorlatinib, a follow-up to its first-generation Xalkori product which is facing increasing competition. ... Lorlatinib was developed by Pfizer scientists with the specific goal of

• Roche gets FDA OKs for Alecensa and Zelboraf

  Roche’s oncology business unit chalked up two FDA approvals this week for its new ALK inhibitor Alecensa in first-line lung cancer and BRAF inhibitor Zelboraf in a rare blood ... That allows Roche’s drug to take on Pfizer’s drug - as well as